Somatostatin analogs in the diagnosis and treatment of cancer

Trends in Endocrinology and Metabolism

Volumn 13, Issue 10, 2002, Pages 451-457

  Lamberts, Steven W J ^a   De Herder, Wouter W ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AN 51; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BIM 23244; BIM 23A387; COMPLEMENTARY DNA; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOXORUBICIN DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GROWTH HORMONE; KI 67 ANTIGEN; LANREOTIDE[YTTRIUM 90 DOTA]; LUTETIUM; LUTETIUM 177; METHOTREXATE; OCTREOTIDE; OCTREOTIDE[3 TYROSINE DTPA]; OCTREOTIDE[3 TYROSINE LUTETIUM 177 DOTA]; OCTREOTIDE[3 TYROSINE YTTRIUM 90 DOTA]; OCTREOTIDE[3 TYROSINE]; PASIREOTIDE; PENTETIC ACID; PENTETREOTIDE IN 111; RADIOISOTOPE; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BRAIN TUMOR; BREAST CARCINOMA; CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER SCINTISCANNING; CANCER SURVIVAL; CANCER THERAPY; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HALF LIFE; GASTRINOMA; GENE THERAPY; GENE TRANSFER; HORMONE RECEPTOR INTERACTION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOMODULATION; INSULINOMA; INTERNALIZATION; KIDNEY CANCER; LEUKOPENIA; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SCINTIGRAPHY; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; CARCINOMA, NEUROENDOCRINE; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASM TRANSPLANTATION; RADIOTHERAPY; RECEPTORS, SOMATOSTATIN; RODENTIA; SOMATOSTATIN;

EID: 0038069184     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(02)00667-7     Document Type: Review

References (57)

1. Guillemin, R. (1978) Peptides in the brain: the new endocrinology of the neuron. Science 202, 390-402
2. Patel, Y.C. (1999) Somatostatin and its receptor family. Front. Neuroendocrinol. 20, 157-198
3. Lamberts, S.W. et al. (1996) Octreotide. N. Engl. J. Med. 334, 246-254
4. Lamberts, S.W. et al. (2002) New somatostatin analogs: will they fulfil old promises? Eur. J. Endocrinol. 146, 701-705
5. Lamberts, S.W. et al. (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12, 450-482
6. Ferjoux, G. et al. (2000) Signal transduction of somatostatin receptors negatively controlling cell proliferation. J. Physiol. Paris 94, 205-210
7. Florio, T. et al. (1999) Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. 13, 24-37
8. Pages, P. et al. (1999) sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J. Biol. Chem. 274, 15186-15193
9. Sharma, K. et al. (1996) Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol. Endocrinol. 10, 1688-1696
10. Sharma, K. et al. (1999) C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol. Endocrinol. 13, 82-90
11. Schally, A.V. et al. (2001) Hypothalamic hormones and cancer. Front. Neuroendocrinol. 22, 248-291
12. Woltering, E.A. et al. (1997) Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest. New Drugs 15, 77-86
13. Reubi, J.C. et al. (2001) Somatostatin receptor sstl-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28, 836-846
14. Watson, J.C. et al. (2001) Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br. J. Cancer 85, 266-272
15. Mentlein, R. et al. (2001) Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int. J. Cancer 92, 545-550
16. Albini, A. et al. (1999) Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J. 13, 647-655
17. Delesque, N. et al. (1997) Sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res. 57, 956-962
18. Rochaix, P. et al. (1999) Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum. Gene Ther. 10, 995-1008
19. Benali, N. et al. (2000) Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc. Natl. Acad. Sci. U. S. A. 97, 9180-9185
20. Reubi, J.C. et al. (1990) Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 39, 78-81
21. Losa, M. et al. (2001) Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 86, 5194-5200
22. Arnold, R. et al. (2000) Treatment of neuroendocrine GEP tumours with somatostatin analogues. Digestion 62 (Suppl. 1), 84-91
23. Shojamanesh, H. et al. (2002) Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94, 331-343
24. Hofland, L.J. and Lamberts, S.W. (2002) The physiological and pathophysiological consequences of somatostatin receptor internalization, desensitization and resistance. In New Developments in Endocrinology: The Expanding Role of Octreotide (Lamberts, S.W.J. and Dogliotti L., eds), pp. 89-98, Bioscientifica
25. Kwekkeboom, D. et al. (2000) Peptide receptor imaging and therapy. J. Nucl. Med. 41, 1704-1713
26. Lamberts, S.W. et al. (2001) Neuroendocrine tumor markers. Front. Neuroendocrinol. 22, 309-339
27. Termanini, B. et al. (1997) Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112,335-347
28. Lugtenburg, P.J. et al. (2001) Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. J. Nucl. Med. 42, 222-229
29. Jensen, R.T. (2000) Editorial: somatostatin receptor-based scintigraphy and antitumor treatment - an expanding vista? J. Clin. Endocrinol. Metab. 85, 3507-3508
30. Traub, T. et al. (2001) 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J. Nucl. Med. 42, 1309-1315
31. Blum, J. et al. (2000) A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 117, 1232-1238
32. Reubi, J.C. et al. (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27, 273-282
33. Papotti, M. et al. (2001) Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch. 439, 787-797
34. Virgolini, I. et al. (2001) Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111DOTA-Tyr3- octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann. Oncol. 12, S41-45
35. Wangberg, B. et al. (1996) Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide. Br. J. Cancer 73, 770-775
36. Schirmer, W.J. et al. (1993) Intraoperative localization of neuroendocrine tumors with 125I-TYR(3)-octreotide and a hand-held γ-detecting probe. Surgery 114, 745-752
37. Nilsson, S. et al. (1995) Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Cancer Res. 55, 5805s-5810s
38. Sinisi, A.A. et al. (1997) Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. J. Clin. Endocrinol. Metab. 82, 2566-2569
39. Halmos, G. et al. (2000) High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J. Clin. Endocrinol. Metab. 85, 2564-2571
40. Hofland, L.J. and Lamberts, S.W. (2001) Somatostatin receptor subtype expression in human tumors. Ann. Oncol. 12, S31-36
41. van Eijck, C.H. et al. (1994) Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343, 640-643
42. Ingle, J.N. et al. (1999) A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85, 1284-1292
43. Kouroumalis, E. et al. (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42, 442-447
44. Hofland, L.J. et al. (1999) Internalization of [DOTA,125I-Tyr3]octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Proc. Assoc. Am. Phys. 111, 63-69
45. Hukovic, N. et al. (1996) Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 137, 4046-4049
46. Schally, A.V. and Nagy, A. (1999) Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol. 141, 1-14
47. Plonowski, A. et al. (2000) Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res. 60, 2996-3001
48. Nagy, A. and Schally, A.V. (2001) Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers. Drugs of the Future 26, 261-270
49. Breeman, W.A. et al. (2001) Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. J. Nucl. Med. 28, 1421-1429
50. Stolz, B. et al. (1998) The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur. J. Nucl. Med. 25, 668-674
51. Kwekkeboom, D.J. et al. (2001) [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur. J. Nucl. Med. 28, 1319-1325
52. Krenning, E. et al. (2002) Somatostatin receptor targeted-radiotherapy of tumors, preclinical and clinical findings. In New Developments in Oncology: the Expanding Role of Octreotide (Lamberts, S.W.J. and Dogliotti, L., eds), pp. 211-227, Bioscientifica
53. Rocheville, M. et al. (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157
54. Rocheville, M. et al. (2000) Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275, 7862-7869
55. Saveanu, A. et al. (2001) Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J. Clin. Endocrinol. Metab. 86, 140-145
56. Zatelli, M.C. et al. (2001) Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J. Clin. Endocrinol. Metab. 86, 2161-2169
57. Bruns, C. et al. (2002) SOM230: a new somatostatin peptidomimetic with a broad SRIF receptor binding and a unique inhibitory profile. Eur. J. Endocrinol. 146, 707-716